Claims

1. A composition comprising pellets, said pellets comprising or consisting of:
   a) a pellet core;
   b) a drug layer covering the core, the drug layer comprising a compound of formula (I)



formula (I), or a pharmaceutically acceptable salt thereof,
   c) a barrier coating layer comprising a film forming agent, wherein said layer covers the drug layer in b), and
   d) an extended release layer comprising one or more extended release polymer(s); wherein said extended release layer covers the barrier coating in c).

2. The composition according to claim 1, wherein the drug layer further comprises a binder selected from cellulose derivatives, such as hydroxypropylmethyl cellulose (HPMC); polyalkylene glycols, such as PEO, and polyvinyl pyrrolidone (PVP), hydroxypropyl cellulose and gelatin, such as wherein the drug layer comprises the binder in an amount from 0.5 to 10% by weight of the pellets.

3. The composition according to claim 2, wherein the binder is HPMC, such as wherein the drug layer comprises HPMC in an amount from 1% to 5% by weight of the pellets.

4. The composition according to any one of the preceding claims, wherein the drug layer further comprises additional excipients selected from: pH modifiers and/or stabilizers, such as wherein the stabilizer is sodium sulphite, such as wherein the drug layer further comprises sodium sulphite in an amount from 0.05 % to 1% by weight of the pellets.

5. The composition according to any one of the preceding claims, wherein the pellet core consists of or comprises spheres made of a material selected from: microcrystalline cellulose (MCC); sugars, such as sucrose, xylitol, mannitol, and

lactose; starch, silica, tartaric acid, and calcium carbonate, preferably microcrystalline cellulose (MCC).

6. The composition according to any one of the preceding claims, wherein the drug layer comprises the compound of formula (I) in an amount of 0.5% to 5 % by weight of the pellets, such as in an amount of 2.5% to 3.5% by weight of the pellets.

7. The composition according to any one of the preceding claims, wherein the barrier coating layer comprises the film forming agent in an amount between 0.5% and 5% by weight of the pellets, optionally wherein the film forming agent is selected from hydroxypropyl methyl cellulose (HPMC), cellulose derivatives, polyacrylates, polymethacrylates and copolymers of acrylate and methacrylate and polyvinylalcohol (PVA), preferably HPMC.

8. The composition according to any one of the preceding claims, wherein the one or more extended release polymer(s) is present in an amount of 0.5% to 10 % by weight of the pellets.

9. The composition according to any one of the preceding claims, wherein the extended release polymer is ethylcellulose, such as wherein the extended release layer comprises ethylcellulose in an amount from 1% to 5% by weight of the pellets.

10. The composition according to any one of the preceding claims, wherein the extended release layer further comprises a film forming agent, optionally wherein the extended release layer comprises the film forming agent in an amount from 0.5% to about 5% by weight of the pellets, such wherein the film forming agent is HPMC.

11. The composition according to any one of the preceding claims, wherein the extended release layer further comprises:
i) a plasticizer, optionally plasticizer selected from: esters derived from citric acid, such as triethyl citrate or tributyl citrate; acetylated monoglycerides; esters of phthalic acid; polyethylene glycol or derivatives thereof; and sorbitol, or mixtures thereof; preferably triethyl citrate and/or
ii) an antitacking agent, optionally selected from: stearates or fatty acid salts of

calcium or magnesium, talc, silica, and silicates or combinations thereof, preferably magnesium stearate.

12. The composition according to any one of the preceding claims, wherein the compound is exo-7-[(8-azabicyclo[3.2.1]octan-3-yl)oxy]-3-methoxy-chromen-2-one or a pharmaceutically acceptable salt thereof, such as hydrochloride salt.

13. The composition according to any one of the preceding claims, wherein the composition is an extended release composition of an active ingredient consisting of a compound of formula (I),



formula (I), or a pharmaceutically acceptable salt thereof, the composition comprising pellets, said pellets comprising or consisting of:

a) an inert pellet core comprising microcrystalline cellulose (MCC);
b) a drug layer comprising: the compound of formula (I) or a pharmaceutically acceptable salt thereof in an amount of 0.5% to 5% by weight of the pellets, HPMC in an amount of 0.5% to 5% by weight of the pellets, and optionally sodium sulphite,
wherein the drug layer covers the inert core;
c) a barrier layer comprising HPMC in an amount of 0.5% to 5% by weight of the pellets, wherein the barrier coating layer covers the drug layer in b); and
d) an extended release layer comprising ethyl cellulose in an amount of 0.5 to 10% by weight of the pellets and HPMC in an amount from 0.5% to 5% by weight of the pellets, wherein the extended release layer covers the barrier coating layer in c).

14. The composition according to any one of the preceding claims, wherein the composition is for oral administration and is in the form of a pharmaceutical dosage form or a unit dosage form, such as a capsule.

15. The composition according to any one of the preceding claims, wherein the composition comprises from 0.5 mg to 25 mg, such as 0.5 mg, such as 1mg, 1.5 mg, 2mg, 2.5mg, 3mg, 3.5mg, 4mg, 4.5mg, 5mg, 6mg, 7mg, 8mg, 9mg, 10mg, 11mg, 12mg, 13mg, 14mg, 15mg, 16mg, 17mg, 18mg, 19mg, 20mg, 21mg, 22mg, 23mg, 24mg, or 25 mg of the compound of formula (I), preferably 5 mg or 10 mg of the compound of formula (I).